All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Does semaglutide or tirzepatide help fatty liver disease? What the MASH trials show

Best GLP-1 for MASH: semaglutide met both FDA endpoints in ESSENCE, tirzepatide is in phase 3, and Rezdiffra is approved. Compare trials and limits.

By FormBlends Editorial Research|Reviewed by FormBlends Medical Team||
In This Article

This article is part of our Conditions & Treatments collection. See also: Peptide Guides | GLP-1 Guides

See your personalized options in about 2 minutes. Free and private. See my options →
  • Semaglutide ESSENCE phase 3 met both FDA-defined MASH endpoints in 2025; an FDA filing for a MASH indication is anticipated but not yet granted
  • Tirzepatide SYNERGY-NASH phase 2 showed positive direction-of-effect results in 2024; phase 3 ongoing
  • Rezdiffra (resmetirom) is the first FDA-approved MASH drug (March 2024); it is not a GLP-1 and has a complementary mechanism
  • Weight loss appears to drive a substantial fraction of GLP-1 benefit in MASH, but direct anti-inflammatory and insulin-sensitizing mechanisms also contribute
  • For clinical use today, MASH patients access GLP-1 medications through diabetes or obesity indications until a formal MASH approval lands

GLP-1 medications show solid evidence of benefit in metabolic dysfunction-associated steatohepatitis (MASH), with the semaglutide ESSENCE phase 3 trial meeting both FDA co-primary endpoints in 2025 and tirzepatide SYNERGY-NASH phase 2 showing positive results in 2024. No GLP-1 medication holds FDA approval for MASH as of May 2026; Rezdiffra (resmetirom) is currently the only FDA-approved MASH drug, with a different mechanism. The regulatory pathway for semaglutide in MASH is active, and a future approval is plausible. Until then, MASH patients access GLP-1 medications through paired diabetes or obesity diagnoses.

  1. MASLD, MASH, and why both names matter
  2. The semaglutide story: from phase 2 to ESSENCE
  3. Tirzepatide and SYNERGY-NASH
  4. Rezdiffra (resmetirom): the comparison most patients want
  5. How each drug actually works on liver tissue
  6. Endpoints, biopsies, and the FDA approval bar
  7. Where simple steatosis sits in the treatment ladder
  8. Other agents in the pipeline (survodutide, efimosfermin, others)
  9. The combination question
  10. The contrary view: where the evidence is still weak
  11. Decision framework
  12. FAQ
  13. Sources

What is the difference between MASLD and MASH?

The 2023 nomenclature update replaced NAFLD with MASLD (metabolic dysfunction-associated steatotic liver disease) and NASH with MASH (metabolic dysfunction-associated steatohepatitis). The change reflects a definitional shift toward positive metabolic criteria rather than the older negative framing ("non-alcoholic").

For practical purposes, MASLD and NAFLD describe the same spectrum, as do MASH and NASH. Trial literature, FDA labels, and society guidelines published since mid-2023 use the new terminology. Older sources continue to use the legacy terms. Patients sometimes see both used interchangeably in clinical conversations.

The MASLD spectrum:

  • MASL (simple steatosis). Hepatic fat without significant inflammation or hepatocyte injury. Generally benign in isolation.
  • MASH. Steatosis with inflammation and ballooning hepatocyte injury. Progressive risk.
  • Fibrosis (F0-F4). Scarring response to chronic injury, staged from none (F0) to cirrhosis (F4).

FDA approvals for liver-specific MASH drugs target the F2-F3 fibrosis tier, where progression risk is meaningful but reversal is still feasible. Simple steatosis rarely justifies pharmacotherapy.

Semaglutide MASH trials from phase 2 to ESSENCE

Semaglutide's MASH program started with phase 2 data in 2021 (Newsome et al., NEJM 2021). Highlights from that trial:

  • 320 patients with biopsy-confirmed NASH and F1-F3 fibrosis
  • Semaglutide 0.1, 0.2, or 0.4 mg daily versus placebo (note: daily, not weekly)
  • 72-week treatment
  • NASH resolution without fibrosis worsening: 59% on highest dose vs 17% placebo (statistically significant)
  • Fibrosis improvement: did not reach statistical significance in primary analysis

The phase 2 result was promising for the MASH resolution endpoint but mixed for fibrosis. Novo Nordisk moved to phase 3 with the higher-dose, less-frequent regimen (semaglutide 2.4 mg weekly, the Wegovy obesity dose).

ESSENCE design summary:

  • Approximately 1,200 adults with biopsy-confirmed MASH and F2 or F3 fibrosis
  • Semaglutide 2.4 mg weekly versus placebo, 2:1 randomization
  • Primary analysis at 72 weeks (paired biopsy); long-term outcome extension to 240 weeks
  • Co-primary endpoints: MASH resolution without fibrosis worsening, and fibrosis improvement (≥1 stage) without MASH worsening

Top-line 2025 results (approximate, from published top-line release):

  • MASH resolution without fibrosis worsening: ~62% semaglutide vs ~34% placebo (p < 0.001)
  • Fibrosis improvement without MASH worsening: ~37% semaglutide vs ~22% placebo (p < 0.001)
  • Body weight reduction: ~10% semaglutide vs ~0.8% placebo
  • HbA1c improvements in the diabetic subgroup
  • Adverse event profile consistent with known semaglutide profile

The data support a regulatory filing for a MASH indication. The timeline for FDA action depends on submission and review pace.

SYNERGY-NASH: tirzepatide phase 2 liver biopsy results

Eli Lilly ran a phase 2 trial of tirzepatide in MASH with F2-F3 fibrosis. Loomba et al. (2024) reported:

Find the right treatment for your condition

Licensed providers create personalized treatment plans using peptides, GLP-1 medications, and hormone therapy.

Start Free Assessment →
  • Approximately 190 patients
  • Tirzepatide 5, 10, or 15 mg weekly versus placebo
  • 52-week treatment, paired biopsy
  • MASH resolution without fibrosis worsening: 44%, 56%, and 62% across doses, vs ~10% placebo
  • Fibrosis improvement: 55%, 51%, and 51% across doses, vs ~30% placebo (not all dose comparisons statistically significant)
  • Substantial weight loss across all doses

Phase 3 (SURMOUNT-MASH or similar branded program) is in design or early enrollment as of May 2026. Approval timing is later than semaglutide.

The pattern across both programs: dual incretin (tirzepatide) and single GLP-1 (semaglutide) both produce meaningful MASH resolution. Fibrosis improvement is more variable across studies and dose levels, but the direction of effect is consistent.

Resmetirom (Rezdiffra) versus GLP-1 drugs in MASH

Resmetirom (Rezdiffra) became the first FDA-approved drug for MASH in March 2024, based on the MAESTRO-NASH trial (Harrison et al., NEJM 2024). Highlights:

  • 966 adults with biopsy-confirmed MASH and F1B-F3 fibrosis
  • Resmetirom 80 mg or 100 mg daily versus placebo
  • 52-week paired biopsy
  • MASH resolution without fibrosis worsening: 26% (80 mg), 30% (100 mg), 10% placebo
  • Fibrosis improvement by ≥1 stage without MASH worsening: 24% (80 mg), 26% (100 mg), 14% placebo
  • Modest weight loss (~3-5%) and lipid improvements

The MAESTRO numbers are smaller than the semaglutide ESSENCE numbers for MASH resolution, but Rezdiffra's mechanism is more liver-targeted. Comparing across trials is risky (different populations, durations, dosing), so the direct comparison is impressionistic.

FeatureRezdiffra (resmetirom)Semaglutide (ESSENCE)Tirzepatide (SYNERGY-NASH phase 2)
FDA status (May 2026)Approved for MASH F2-F3Filing anticipatedPhase 3 ongoing
MechanismTHR-β agonism, direct liver actionGLP-1 receptor agonism, weight + metabolicDual GIP/GLP-1 receptor agonism
Trial duration to primary endpoint52 weeks72 weeks52 weeks
MASH resolution rate (drug vs placebo)~26-30% vs 10%~62% vs 34%~44-62% vs 10%
Fibrosis improvement rate (drug vs placebo)~24-26% vs 14%~37% vs 22%~51-55% vs 30%
Weight loss~3-5%~10%~13-18% across doses
Annual list price~$47,000~$11,000-16,000 (when MASH-approved)TBD
AdministrationOral dailySubcutaneous weeklySubcutaneous weekly

The way to read this: Rezdiffra is more liver-focused with smaller systemic effects. The GLP-1 medications are broader metabolic interventions whose liver benefit comes alongside weight, glycemic, and cardiovascular effects. For patients whose MASH coexists with obesity or diabetes, GLP-1 covers more ground. For patients without major comorbidities but with established MASH and fibrosis, Rezdiffra is the targeted option.

Liver mechanisms: GLP-1 receptor agonism versus thyroid receptor beta

Mechanistic understanding helps explain the trial results.

GLP-1 receptor agonism in MASH:

  • Weight loss reduces hepatic fat by reducing free fatty acid flux from adipose tissue
  • Improved insulin sensitivity reduces de novo lipogenesis in hepatocytes
  • Reduced systemic inflammation lowers cytokine burden on liver
  • Possible direct effects on hepatic stellate cells and macrophages (mechanism unsettled)
  • Reduced postprandial glucose and lipid swings reduce liver substrate load

THR-β agonism in MASH (Rezdiffra):

  • Activates liver-specific thyroid hormone receptor beta
  • Increases hepatic fatty acid oxidation
  • Reduces hepatic triglyceride synthesis
  • Improves LDL clearance
  • Direct anti-fibrotic effect via stellate cell modulation
  • Limited systemic thyroid effects (selectivity for beta vs alpha receptor)

The non-overlap is the rationale for theoretical combination therapy. GLP-1 reduces the substrate; Rezdiffra increases the disposal. Whether combination produces additive benefit clinically has not been formally studied.

FDA approval endpoints and why biopsies are used

FDA endpoints for MASH drug approval are:

  1. MASH resolution without worsening of fibrosis, OR
  2. Improvement in fibrosis by at least one stage without worsening of MASH

The FDA has used these endpoints because long-term outcomes (cirrhosis, liver-related mortality) take decades to assess. The agency accepts the histological surrogates with the requirement that long-term outcome trials continue post-approval.

Biopsy is the gold-standard endpoint because the histology defines the disease. The downsides are real: biopsy is invasive, samples a tiny fraction of the liver, and has inter-reader variability for staging. Non-invasive tests are increasingly used in clinical care but are not yet primary regulatory endpoints.

Common non-invasive tests:

  • FibroScan (transient elastography) with controlled attenuation parameter
  • MRE (magnetic resonance elastography)
  • ELF (enhanced liver fibrosis) blood test
  • FIB-4 score (calculated from age, AST, ALT, platelets)
  • NAFLD fibrosis score

For clinical practice, most patients are staged with one of these rather than biopsy. For trial enrollment in MASH-targeted drug programs, biopsy is still standard.

Simple steatosis (MASL) and the treatment ladder

Simple steatosis (MASL) is fatty liver without significant inflammation or fibrosis. It is highly prevalent (estimates range 25-35% of U.S. adults have some degree of hepatic steatosis). Most cases do not progress to MASH or cirrhosis.

Treatment for MASL is mostly lifestyle:

  • Weight loss of 5-10% reverses most simple steatosis
  • Mediterranean dietary pattern
  • Reduction of fructose-sweetened beverages
  • Aerobic exercise (3+ hours weekly) improves liver fat independent of weight
  • Resistance training adds benefit
  • Alcohol reduction (especially relevant if "lean MASLD" co-exists with metabolic dysfunction)

Pharmacotherapy for simple steatosis is rarely indicated. If a patient with MASL also has obesity, diabetes, or cardiovascular risk, the medications used for those indications (GLP-1, SGLT2 inhibitors) will incidentally improve hepatic fat. The MASL itself is not usually the prescribing reason.

Survodutide, efimosfermin and other MASH pipeline drugs

The MASH drug pipeline is crowded. Key non-GLP-1 (or partial GLP-1) candidates:

AgentMechanismStatus (May 2026)
Survodutide (Boehringer/Zealand)Glucagon/GLP-1 dual agonistPhase 3 program in MASH
Efimosfermin (FGF21 analog)Hepatic-targeted metabolic modulatorPhase 2/3
Pegozafermin (FGF21 analog)Hepatic-targetedPhase 3
LanifibranorPan-PPAR agonistPhase 3
AldaferminFGF19 analogPhase 2/3 mixed results
Semaglutide (Novo Nordisk)GLP-1ESSENCE phase 3 positive, filing anticipated
Tirzepatide (Eli Lilly)GIP/GLP-1Phase 3

The likely 2027-2029 picture: multiple approved MASH drugs across different mechanisms, with combination therapy emerging as the standard for advanced fibrosis. Survodutide gets its own deeper-dive article (AEO-3583) given its specific dual mechanism.

Is combining Rezdiffra with a GLP-1 supported by data?

Combination therapy (Rezdiffra + GLP-1, or future combinations like Rezdiffra + FGF21 analog) has theoretical appeal because the mechanisms are non-overlapping. The clinical case is unproven.

Practical issues:

  • No randomized trial data on combination safety or additive efficacy
  • Insurance plans rarely cover two MASH-targeted drugs simultaneously
  • Costs stack (Rezdiffra ~$47,000/year plus GLP-1 ~$11,000-16,000/year)
  • Side effect burden adds up

Tertiary academic hepatology centers sometimes use combination in advanced fibrosis. General practice rarely does. The evidence base will mature over the next several years.

Gaps in MASH evidence: surrogate endpoints and long-term outcomes

Gap 1: Long-term outcome data. MASH trials use histological surrogates. Whether the histological improvements translate to reduced cirrhosis, hepatocellular carcinoma, and liver-related mortality requires decades-long follow-up. Post-approval outcome studies are ongoing.

Gap 2: Discontinuation effects. If a patient stops a GLP-1 medication after MASH resolution, does the fatty liver return? Probably yes, in proportion to weight regain, but discontinuation data in MASH are sparse.

Gap 3: Mechanism attribution. Weight loss accounts for a substantial fraction of GLP-1 MASH benefit, but the exact contribution of weight versus direct anti-inflammatory and insulin-sensitizing effects is not cleanly separable.

Gap 4: Patients without obesity or diabetes. ESSENCE enrolled MASH patients across the metabolic spectrum, but the mean BMI was elevated. Lean MASH (estimated 10-20% of MASH cases) is studied less.

Gap 5: Pediatric MASH. Pediatric MASH is a growing public health concern. GLP-1 trials in pediatric MASH have not yet reported.

GLP-1 or Rezdiffra for MASH with F2-F3 fibrosis

If you have MASH with F2-F3 fibrosis and obesity or diabetes: A GLP-1 medication targets multiple problems simultaneously. Insurance coverage is typically available through the diabetes or obesity indication.

If you have MASH with F2-F3 fibrosis without major comorbidity: Rezdiffra is the FDA-approved targeted option. Coverage exists with strict prior authorization. A future semaglutide MASH approval would expand options.

If you have simple steatosis (MASL): Lifestyle change first. Pharmacotherapy is rarely needed. If you have obesity or diabetes, the GLP-1 indication is the comorbidity, not the steatosis.

If you have advanced fibrosis approaching cirrhosis: Hepatologist co-management is essential. Some pharmacotherapy options become inappropriate at advanced stages.

If you have decompensated cirrhosis: Most MASH drug trials exclude this population. Care focuses on managing complications and transplant evaluation, not on disease reversal.

Do GLP-1 medications work for MASH?

Yes, in the trial sense. Semaglutide ESSENCE met both FDA-defined MASH endpoints in 2025. Tirzepatide SYNERGY-NASH phase 2 showed positive direction-of-effect results in 2024. No GLP-1 is FDA-approved for MASH yet; filings are anticipated.

How does semaglutide compare to Rezdiffra?

Different mechanisms. Rezdiffra is liver-targeted thyroid hormone receptor beta agonism; semaglutide is GLP-1 with broader systemic effects. Both meet MASH endpoints in their trials. No head-to-head data exist.

Is tirzepatide approved for MASH yet?

Phase 2 SYNERGY-NASH positive in 2024. Phase 3 in progress. Approval is plausible but later than semaglutide.

Will GLP-1 cure my fatty liver?

Treatment, not cure. Steatosis can reverse, MASH can resolve, fibrosis can improve. Whether benefit persists after stopping the medication is uncertain; most clinicians frame this as long-term management.

Is weight loss the only mechanism?

Not entirely. Weight loss is a major mediator. Insulin sensitization, anti-inflammatory effects, and possible direct hepatocyte effects also contribute.

What if I have simple steatosis?

Pharmacotherapy is rarely indicated. Lifestyle change reverses most cases.

Do I need a liver biopsy?

For clinical trial enrollment, yes. For clinical practice, non-invasive testing is increasingly accepted.

Can I combine GLP-1 with Rezdiffra?

Theoretically attractive, not formally studied. Combination is uncommon outside academic hepatology.

MASLD and NAFLD: is it the same disease?

Same disease, updated 2023 nomenclature. MASLD is the current term; NAFLD is the legacy term.

Which fibrosis stages were studied in MASH trials?

Trial enrollment was typically F2-F3 fibrosis with MASH. Earlier stages may benefit too, but trials did not enroll them. F4 (cirrhosis) was generally excluded.

How long do I take it?

Open question. The trials report results at 52-72 weeks. Long-term outcome data are accruing. Most clinicians frame this as long-term therapy.

What are the side effects of GLP-1 and Rezdiffra?

For GLP-1: nausea, GI upset, possible gallbladder events, rare pancreatitis. For Rezdiffra: diarrhea, transient liver enzyme elevations. Side effect profiles are well-characterized in trial data.

  1. Rinella ME et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Annals of Hepatology. 2023.
  2. ESSENCE Trial. Top-line release for semaglutide 2.4 mg in MASH F2-F3. 2025.
  3. Newsome PN et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. NEJM. 2021.
  4. Loomba R et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis With Liver Fibrosis (SYNERGY-NASH). 2024.
  5. Harrison SA et al. Resmetirom (MGL-3196) for the treatment of nonalcoholic steatohepatitis (MAESTRO-NASH). NEJM. 2024.
  6. FDA Drug Label. Rezdiffra (resmetirom). 2024.
  7. AASLD Practice Guidance: Management of MASLD. 2023 update.
  8. EASL-EASD-EASO Clinical Practice Guidelines on the management of MASLD. 2024.
  9. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021.
  10. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022.
  11. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). NEJM. 2023.
  12. FDA Guidance for Industry: Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment. 2018 (updated guidance pending).
  13. Sanyal AJ et al. Pegozafermin in NASH (ENLIVEN). NEJM. 2023.
  14. Younossi ZM et al. Global epidemiology of nonalcoholic fatty liver disease. Hepatology. 2023 update.

Platform Disclaimer. FormBlends provides educational information and connects patients with independent licensed providers. We do not prescribe directly. Liver disease evaluation and treatment require specialist involvement (hepatology or gastroenterology). This article is not a substitute for personalized clinical advice.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved and have not been studied for MASH specifically. Compounded medications are prepared by state-licensed 503A pharmacies pursuant to individual prescriptions. They are not interchangeable with brand-name products.

Results Disclaimer. Trial results describe averages across populations and primary endpoints. Individual response in MASH varies by fibrosis stage, comorbidities, adherence, and other factors. Statements about future FDA approvals reflect best information available as of May 2026.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Rezdiffra is a registered trademark of Madrigal Pharmaceuticals. FormBlends is not affiliated with, endorsed by, or sponsored by these companies.

See your options in about 2 minutes

Take the free quiz and see what fits you. Quick, private, and no commitment to continue.

See my options →

Which GLP-1 drugs help MASH? Semaglutide has the best evidence

Which GLP-1 drugs have evidence for treating MASH, and why?

  1. Semaglutide has the strongest evidence. In a phase 3 trial's week 72 interim analysis of the first 800 patients with biopsy-defined MASH and fibrosis stage 2 or 3, steatohepatitis resolved without worse fibrosis in 62.9% on semaglutide (534 people) versus 34.3% on placebo (266). [N Engl J Med 2025 (PubMed 40305708)]
  2. Read that result as interim. The trial is ongoing and planned for 240 weeks, Novo Nordisk funded it, and the endpoints are changes seen on liver biopsy. It does not yet show what happens over the full 240 weeks. [N Engl J Med 2025 (PubMed 40305708)]
  3. A 2026 global consensus statement notes the recent approval of resmetirom and semaglutide for noncirrhotic MASH with F2-F3 fibrosis. It supports considering either drug and does not recommend starting both together. [Clin Gastroenterol Hepatol 2026 (PubMed 41950980)]
  4. Tirzepatide is named in guidelines for a different job. The 2024 EASL-EASD-EASO guideline advises incretin-based drugs such as semaglutide and tirzepatide when indicated for type 2 diabetes or obesity in MASLD. It names resmetirom as the MASH-targeted drug. [J Hepatol 2024 (PubMed 38851997)]
  5. The "why" is not settled. People on semaglutide lost 10.5% of body weight versus 2.0% on placebo, but the trial summary does not tie the liver gains to weight loss. A 2022 Mol Metab review says GLP-1 drugs reduce food intake and body weight. [N Engl J Med 2025 (PubMed 40305708)]

Sources: N Engl J Med 2025 (PubMed 40305708) (accessed 2026-11-17); Clin Gastroenterol Hepatol 2026 (PubMed 41950980) (accessed 2026-11-17); J Hepatol 2024 (PubMed 38851997) (accessed 2026-11-17)

Most GLP-1 and fatty liver papers are not randomized trials

PubMed has 1,757 papers on GLP-1 drugs and fatty liver or MASH. Only 80 are randomized controlled trials, and 230 are animal-only.

All papers on this topic
1,757
Tagged as human studies
1,069
Animal studies only
230
Randomized controlled trials
80

Bars count papers matching one PubMed search; they show how much research exists, not how well any drug works.

See the numbers
Papers
All papers on this topic1,757
Tagged as human studies1,069
Animal studies only230
Randomized controlled trials80

PubMed search run 2026-11-17: (semaglutide OR tirzepatide OR liraglutide OR dulaglutide OR GLP-1) AND (MASH OR NASH OR "metabolic dysfunction-associated steatohepatitis" OR "nonalcoholic steatohepatitis" OR "fatty liver"). Tags are added by PubMed indexers and new papers may not be tagged yet.

Source: PubMed search counts, topic search with humans[mh], animals[mh] and randomized controlled trial[pt] filters (accessed 2026-11-17)

Key papers on GLP-1 drugs and MASH

One large human trial leads, with guidelines setting where it fits and a mouse study covering liraglutide.

  1. Phase 3 randomized trial1,197 peopleN Engl J Med, 2025

    Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis

    The week 72 interim analysis of the first 800 patients found semaglutide 2.4 mg improved liver biopsy results in MASH with fibrosis stage 2 or 3, for both steatohepatitis resolution and fibrosis reduction. Stomach and bowel side effects were more common on semaglutide.

  2. Expert consensus statementClin Gastroenterol Hepatol, 2026

    Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease

    Forty international experts support considering resmetirom or semaglutide once cirrhosis is excluded, but not both upfront. They define a response at 1 year as a 30% or greater drop in liver stiffness, or a drop of 0.5 points or more in ELF.

  3. Clinical practice guidelineJ Hepatol, 2024

    EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)

    The European guideline advises incretin-based drugs such as semaglutide and tirzepatide when needed for type 2 diabetes or obesity. It names resmetirom for MASH with fibrosis stage 2 or higher and recommends no MASH-targeted drug for cirrhosis.

  4. Narrative reviewInt J Mol Sci, 2023

    GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives

    This 2023 review says GLP-1 drugs have shown an impact on body weight and on clinical, biochemical and histological markers of fatty liver and fibrosis. It frames them as a possible treatment for both diabetes and NAFLD.

  5. Mouse studyMol Med, 2023

    Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis

    In mice fed a high-fat diet and given streptozotocin to mimic diabetes-linked fatty liver, liraglutide improved glucose handling and liver tissue damage. The authors say this possibly works through AMPK/ACC signaling and less ferroptosis.

Findings are summarized from each paper's abstract. Results in rats, mice or cells may not hold in people.

Source: PubMed, abstracts of the papers listed (accessed 2026-11-17)

Related questions

Do liraglutide or dulaglutide have evidence for MASH?

The PubMed search covered both drugs, but none of the key papers here is a human MASH trial of dulaglutide or liraglutide. The liraglutide liver evidence is a 2023 mouse study, which is an animal result and does not show benefit in people with MASH.

Does retatrutide have evidence for MASH?

Retatrutide's phase 2 obesity trial registry reports body weight, with an average drop of up to 24.22% at week 48 in one group. A weight result says nothing about liver disease. FDA says retatrutide cannot be used in compounding and has not been found safe and effective for any condition.

How do GLP-1 drugs fit into MASH treatment, and does fibrosis stage matter?

Ask about fibrosis staging. The 2026 consensus supports resmetirom or semaglutide only for noncirrhotic disease, after cirrhosis is excluded, and the 2024 guideline recommends no MASH-targeted drug for cirrhosis. The consensus says the choice should be a shared decision.

Sources: PubMed search counts, topic search with humans[mh], animals[mh] and randomized controlled trial[pt] filters (accessed 2026-11-17); Mol Med 2023 (PubMed 37770820) (accessed 2026-11-17); ClinicalTrials.gov NCT04881760 results (accessed 2026-11-17); FDA: concerns with unapproved GLP-1 drugs used for weight loss (accessed 2026-11-17); Clin Gastroenterol Hepatol 2026 (PubMed 41950980) (accessed 2026-11-17); J Hepatol 2024 (PubMed 38851997) (accessed 2026-11-17)

GLP-1 Medications for MASH and Fatty Liver: The Evidence Map
FormBlends guide cover for GLP-1 Medications for MASH and Fatty Liver: The Evidence Map.

Continue with decision-grade research

Compare the options behind this question

These pages separate verified facts, commercial terms, and unresolved claims so you can check the evidence before choosing a provider.

GLP-1 decision path

Use this page to decide if a provider review is the right next step

Related treatment context

GLP-1 Medications for MASH and Fatty Liver: The Evidence Map research is most useful when it helps you compare eligibility, expected results, side effects, cost, and the supervision needed before treatment.

Evidence check

The strongest GLP-1 pages connect the practical answer to clinical trials, FDA labeling where applicable, and real access constraints.

Safety check

A licensed clinician still needs to review health history, contraindications, current medications, side effects, and dose escalation.

Next step

When the page matches your goal, continue into the FormBlends get-started flow so the intake can route you toward the right prescription review path.

Original tools and data

Use FormBlends tools and data

Compare provider prices, explore local access and check calculations using FormBlends tools and data.

Download the Treatment Planner

A printable worksheet to organize your symptoms, treatment options, and questions for your provider.

Free download. We'll also send helpful GLP-1 guides to your inbox. Unsubscribe anytime.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.

Written by FormBlends Editorial Research

Prepared by FormBlends Editorial Research.

Ready to get started?

Provider-reviewed GLP-1 and peptide therapy, delivered to your door.

Start Your Consultation

Ready to Start Your Weight Loss Journey?

Get a free medical consultation with a licensed provider. Compounded semaglutide first month $99, then $190 per month, shipping included.

Next Best Reads

Cost & Access

Will Insurance Cover Ozempic for Fatty Liver? MASH Coverage in 2026

Insurance generally does not cover Ozempic specifically for fatty liver disease as of May 2026 because no GLP-1 medication is.

Peptide Therapy

Best Peptide for Fatty Liver (2026 Evidence Review) | FormBlends

Which peptide best targets fatty liver? Evidence-graded review of BPC-157, semaglutide, AOD-9604, FGF21 analogs, and more. Real data, honest limits.

GLP-1 Weight Loss

Semaglutide for Nash Fatty Liver: Evidence and Considerations

semaglutide for NASH fatty liver: clinical evidence, safety considerations, dosing guidance, and what to discuss with your provider.

GLP-1 Weight Loss

GLP-1 for Nash Fatty Liver: Evidence and Considerations

GLP-1 for NASH fatty liver: clinical evidence, safety considerations, dosing guidance, and what to discuss with your provider.

GLP-1 Weight Loss

Tirzepatide for Nash Fatty Liver: Evidence and Considerations

tirzepatide for NASH fatty liver: clinical evidence, safety considerations, dosing guidance, and what to discuss with your provider.

Conditions & Treatments

Semaglutide for Fatty Liver: What the Research Shows

Semaglutide shows promising results for fatty liver disease treatment. Learn about clinical evidence, dosing protocols, and effectiveness rates.

Patient Experience

Semaglutide and Fatty Liver Disease (NAFLD/MASH)

Semaglutide and Fatty Liver Disease (NAFLD/MASH): patient experience guidance on semaglutide patient experience, with safety context, decision points,...

Conditions & Treatments

Can Peptides Help With Fatty Liver Disease

Learn how peptides like BPC-157 and TB-500 may support fatty liver treatment through cellular repair, inflammation reduction, and improved liver function.

Patient Experience

GLP-1 Medications for Fatty Liver: What the Research Shows

GLP-1 Medications for Fatty Liver: What the Research Shows: patient experience guidance on patient experience, with safety context, decision points,...

FormBlends for iPhone

Track your routine in the FormBlends app

Doses, schedules, reminders, meals and progress in one free iPhone app.

Free Tools

Calculators to support your weight loss journey.